▎Retatrutid Overview
Retatrutid is a novel peptide drug. As a triple receptor agonist, it acts on the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously. It helps individuals lose weight by comprehensively regulating appetite, enhancing satiety, suppressing hunger, and increasing energy expenditure.
In addition, Retatrutid can also improve multiple cardiometabolic risk indicators, such as blood pressure, glycated hemoglobin, fasting blood glucose, insulin, total cholesterol, low-density lipoprotein cholesterol, and triglycerides. It also has a positive effect on patients with non-alcoholic fatty liver disease, enabling the liver fat content of most participants to return to normal.
Compared with single or dual agonists, Retatrutid regulates blood glucose, body weight, etc. from multiple dimensions by simultaneously activating the three receptors of GLP-1, GIP, and glucagon (GCG). Theoretically, it can more comprehensively improve metabolic disorders and has unique advantages in aspects such as weight loss, reduction of hepatic steatosis, and normalization of blood glucose levels.
The synergistic action of multiple receptors of Retatrutid makes it more effective than existing GLP-1 receptor agonists or dual receptor agonists in regulating metabolism and controlling body weight, providing new treatment options for patients with obesity and type 2 diabetes mellitus.
